Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Wizz CEO: We’re going to invest $1 b. in Israeli market27.11.2025 - 26 Famous Urban communities for Shopping on the planet19.10.2023
- 3Google's proposed data center in orbit will face issues with space debris in an already crowded orbit25.12.2025
- 4Every year, she thanks the trooper for the arrest that led to her sobriety11.12.2025
- 5Kansas school officials report high student illness, dismiss early16.12.2025
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Vote In favor of Your Favored Sort Of Dress
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- The Most Astonishing Arising Advances to Watch
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
